Terms: = Leukemia AND HOXA9, HOX1, 3205, ENSG00000078399, HOX1G, P31269 AND Treatment
77 results:
1. Discovery of novel pyrrolo[2,3-d]pyrimidines as potent menin-mixed lineage leukemia interaction inhibitors.
Bai H; Yang Z; Lei H; Wu Y; Liu J; Yuan B; Ma M; Gao L; Zhang SQ; Xin M
Eur J Med Chem; 2024 Mar; 268():116226. PubMed ID: 38367493
[TBL] [Abstract] [Full Text] [Related]
2. RNA-binding protein RBM5 plays an essential role in acute myeloid leukemia by activating the oncogenic protein hoxa9.
Zhang M; Hyle J; Chen X; Xin Y; Jin Y; Zhang J; Yang X; Chen X; Wright S; Liu Z; Rosikiewicz W; Xu B; He L; Liu H; Ping N; Wu D; Wen F; Li C; Xu P
Genome Biol; 2024 Jan; 25(1):16. PubMed ID: 38216972
[TBL] [Abstract] [Full Text] [Related]
3. MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis.
Meriç N; Albayrak E; Gülbaş Z; Kocabaş F
Leuk Lymphoma; 2024 Feb; 65(2):187-198. PubMed ID: 37902585
[TBL] [Abstract] [Full Text] [Related]
4. Identification and analysis of methylation signature genes and association with immune infiltration in pediatric acute myeloid leukemia.
Zhu H; Xu Y; Xia J; Guo X; Fang Y; Fan J; Li F; Wu J; Zheng G; Liu Y
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14965-14982. PubMed ID: 37606761
[TBL] [Abstract] [Full Text] [Related]
5. Panobinostat (LBH589) increase survival in adult xenografic model of acute lymphoblastic leukemia with t(4;11) but promotes antagonistic effects in combination with MTX and 6MP.
Moreno DA; Junior HLR; Laranjeira ABA; Cruzeiro GAV; Borges KS; Salomão KB; Ramalho FS; Yunes JA; Silva CLA; Rego EM; Scrideli CA; Tone LG
Med Oncol; 2022 Sep; 39(12):216. PubMed ID: 36175721
[TBL] [Abstract] [Full Text] [Related]
6. Bioinformatic Analyses of Broad H3K79me2 Domains in Different leukemia Cell Line Data Sets.
Sharma P; Sattarifard H; Fatemiyan N; Lakowski TM; Davie JR
Cells; 2022 Sep; 11(18):. PubMed ID: 36139405
[TBL] [Abstract] [Full Text] [Related]
7. RNA-binding proteins as drivers of AML and novel therapeutic targets.
Qin T; Cheng Y; Wang X
Leuk Lymphoma; 2022 May; 63(5):1045-1057. PubMed ID: 35075986
[TBL] [Abstract] [Full Text] [Related]
8. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Fiskus W; Boettcher S; Daver N; Mill CP; Sasaki K; Birdwell CE; Davis JA; Takahashi K; Kadia TM; DiNardo CD; Jin Q; Qi Y; Su X; McGeehan GM; Khoury JD; Ebert BL; Bhalla KN
Blood Cancer J; 2022 Jan; 12(1):5. PubMed ID: 35017466
[TBL] [Abstract] [Full Text] [Related]
9. [Clinical Characteristics and Prognosis of Adult Acute Myeloid leukemia with NUP98 Gene Rearrangement].
Lu N; Ding Y; Wu YL; Wang LL; Jing Y; Li HH; Li M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1450-1455. PubMed ID: 34627423
[TBL] [Abstract] [Full Text] [Related]
10. A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for hoxa9 and MEIS1 Dependent AML.
Hassan JJ; Lieske A; Dörpmund N; Klatt D; Hoffmann D; Kleppa MJ; Kustikova OS; Stahlhut M; Schwarzer A; Schambach A; Maetzig T
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502319
[No Abstract] [Full Text] [Related]
11. Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression.
Zhang M; Aguilar A; Xu S; Huang L; Chinnaswamy K; Sleger T; Wang B; Gross S; Nicolay BN; Ronseaux S; Harvey K; Wang Y; McEachern D; Kirchhoff PD; Liu Z; Stuckey J; Tron AE; Liu T; Wang S
J Med Chem; 2021 Jul; 64(14):10333-10349. PubMed ID: 34196551
[TBL] [Abstract] [Full Text] [Related]
12. Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup.
Touzart A; Mayakonda A; Smith C; Hey J; Toth R; Cieslak A; Andrieu GP; Tran Quang C; Latiri M; Ghysdael J; Spicuglia S; Dombret H; Ifrah N; Macintyre E; Lutsik P; Boissel N; Plass C; Asnafi V
Sci Transl Med; 2021 May; 13(595):. PubMed ID: 34039737
[TBL] [Abstract] [Full Text] [Related]
13. Modulators of histone demethylase JMJD1C selectively target leukemic stem cells.
Yang Y; Zhang X; Zhang X; Wang Y; Wang X; Hu L; Zhao Y; Wang H; Wang Z; Wang H; Wang L; Dirks WG; Drexler HG; Xu X; Hu Z
FEBS Open Bio; 2021 Jan; 11(1):265-277. PubMed ID: 33289299
[TBL] [Abstract] [Full Text] [Related]
14. hoxa9/IRX1 expression pattern defines two subgroups of infant MLL-AF4-driven acute lymphoblastic leukemia.
Symeonidou V; Ottersbach K
Exp Hematol; 2021 Jan; 93():38-43.e5. PubMed ID: 33069783
[TBL] [Abstract] [Full Text] [Related]
15. Disruption of CTCF Boundary at HOXA Locus Promote BET Inhibitors' Therapeutic Sensitivity in Acute Myeloid leukemia.
Zha J; Lai Q; Deng M; Shi P; Zhao H; Chen Q; Wu H; Xu B
Stem Cell Rev Rep; 2020 Dec; 16(6):1280-1291. PubMed ID: 33057942
[TBL] [Abstract] [Full Text] [Related]
16. SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
Ropa J; Saha N; Hu H; Peterson LF; Talpaz M; Muntean AG
Haematologica; 2020 Sep; 105(9):2273-2285. PubMed ID: 33054052
[TBL] [Abstract] [Full Text] [Related]
17. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic leukemia: Resistance Pathways Identified by Network Modeling Analysis.
Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR
Mol Cancer Ther; 2020 Sep; 19(9):1809-1821. PubMed ID: 32753387
[TBL] [Abstract] [Full Text] [Related]
18. Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of hoxa9.
Yoshino S; Yokoyama T; Sunami Y; Takahara T; Nakamura A; Yamazaki Y; Tsutsumi S; Aburatani H; Nakamura T
Blood; 2021 Jan; 137(1):75-88. PubMed ID: 32730594
[TBL] [Abstract] [Full Text] [Related]
19. Disclosing the Interactome of Leukemogenic NUP98-hoxa9 and SET-NUP214 Fusion Proteins Using a Proteomic Approach.
Mendes A; Jühlen R; Bousbata S; Fahrenkrog B
Cells; 2020 Jul; 9(7):. PubMed ID: 32664447
[TBL] [Abstract] [Full Text] [Related]
20. Requirement for LIM kinases in acute myeloid leukemia.
Jensen P; Carlet M; Schlenk RF; Weber A; Kress J; Brunner I; Słabicki M; Grill G; Weisemann S; Cheng YY; Jeremias I; Scholl C; Fröhling S
Leukemia; 2020 Dec; 34(12):3173-3185. PubMed ID: 32591645
[TBL] [Abstract] [Full Text] [Related]
[Next]
